Processa Pharmaceuticals, Inc. Proceeds from Issuance of Convertible Preferred Stock
Processa Pharmaceuticals, Inc. (PCSA) reported Proceeds from Issuance of Convertible Preferred Stock of $509.96 thousand for the 12-month period ending 2014-12-31, per its 10-K filed 2017-06-19.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock · last filed 2017-06-19
- Processa Pharmaceuticals, Inc. proceeds from issuance of convertible preferred stock for the quarter ending 2014-12-31 was $0.00.
- Processa Pharmaceuticals, Inc. proceeds from issuance of convertible preferred stock for the quarter ending 2014-09-30 was $0.00.
- Processa Pharmaceuticals, Inc. proceeds from issuance of convertible preferred stock for the quarter ending 2014-06-30 was $355.97K.
- Processa Pharmaceuticals, Inc. proceeds from issuance of convertible preferred stock for the quarter ending 2014-03-31 was $154.00K.
- Processa Pharmaceuticals, Inc. proceeds from issuance of convertible preferred stock for fiscal 2014 was $509.96K, a 62.19% decline from fiscal 2013.
- Processa Pharmaceuticals, Inc. proceeds from issuance of convertible preferred stock for fiscal 2013 was $1.35M.
| Period end | Proceeds from Issuance of Convertible Preferred Stock 3 month | Proceeds from Issuance of Convertible Preferred Stock 6 month | Proceeds from Issuance of Convertible Preferred Stock 9 month | Proceeds from Issuance of Convertible Preferred Stock 12 month | Proceeds from Issuance of Convertible Preferred Stock 27 month | Proceeds from Issuance of Convertible Preferred Stock 30 month | Proceeds from Issuance of Convertible Preferred Stock 33 month | Proceeds from Issuance of Convertible Preferred Stock 36 month |
|---|---|---|---|---|---|---|---|---|
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-06-19 | $0.00 derived: sum of 2 quarters · filed 2017-06-19 | $355.97K derived: sum of 3 quarters · filed 2017-06-19 | $509.96K 10-K · filed 2017-06-19 | ||||
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-12-01 | $355.97K derived: sum of 2 quarters · filed 2015-12-01 | $509.96K 10-Q · filed 2015-12-01 | $509.96K derived: sum of 4 quarters · filed 2015-12-01 | ||||
| 2014-06-30 | $355.97K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-19 | $509.96K 10-Q · filed 2015-08-19 | $509.96K derived: sum of 3 quarters · filed 2015-08-19 | $509.96K derived: sum of 4 quarters · filed 2015-08-19 | ||||
| 2014-03-31 | $154.00K 10-Q · filed 2015-05-15 | $154.00K derived: sum of 2 quarters · filed 2015-05-15 | $154.00K derived: sum of 3 quarters · filed 2015-05-15 | $6.52M 10-Q · filed 2014-05-14 | ||||
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-04-14 | $0.00 derived: sum of 2 quarters · filed 2015-04-14 | $1.35M 10-K · filed 2015-04-14 | $500.00K 10-K · filed 2014-03-27 | ||||
| 2013-09-30 | $0.00 derived: 10-Q 30 month − 10-Q/A 27 month · filed 2013-11-08 | $1.35M 10-Q · filed 2014-11-13 | $500.00K 10-Q · filed 2013-11-08 | |||||
| 2013-06-30 | $500.00K 10-Q/A · filed 2013-09-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |